why choose us

First received: November 02, 2024

Clinical Trial: Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: IBS-D (Diarrhea-predominant)

Study Type: OBSERVATIONAL


Official Title: Evaluation of the Efficacy of Clostridium Butyricum CBM588® on Symptoms and Quality of Life in Patients With Diarrhea-dominant Irritable Bowel Syndrome (PROREDI: (PRObiotic REmedy for DIarrhea)

Brief Summary: Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder affecting 15-20% of people in industrialized countries, often presenting as abdominal discomfort, pain, and altered bowel habits, significantly impacting quality of life.Among IBS subtypes, IBS-D (diarrhea-predominant) is marked by frequent, loose bowel movements, identified using the Bristol Stool Form Scale (BSFS) and classified according to Rome IV criteria.Emerging research indicates that alterations in gut microbiota, particularly a…

Read more